Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Intuitive Surgical is favored over Abbott based on FY2025 revenue growth of 20.5% to $10.1B, a 28.4% net margin, nearly 12,000 da Vinci systems installed, and recurring revenue representing about 85% of sales. Abbott delivered steadier FY2025 results, with revenue up 5.7% to $44.3B, $7.4B in free cash flow, and a planned Exact Sciences acquisition to expand cancer diagnostics. Abbott trades more cheaply at 18.5x forward P/E versus Intuitive's 37.2x, but Intuitive's faster procedure-driven growth and entrenched installed base support its valuation premium.

Analysis

The more actionable implication is a valuation-dispersion trade, not an outright endorsement of either name. ISRG’s premium leaves little tolerance for a procedure-volume deceleration, unfavorable geographic/procedure mix, or a hospital capital-budget pause; even if recurring revenue cushions reported sales, a modest reduction in forward growth expectations can drive material multiple compression. Conversely, ABT’s lower multiple embeds less execution credit for diagnostics and structural heart/diabetes optionality, but its pending EXAS integration introduces deal-spread, reimbursement, and capital-allocation risk that prevents it from functioning as a pure defensive substitute.

Over the next 1-3 months, watch ISRG procedure growth, utilization per installed system, and instrument/service revenue versus placements. A gap between strong placements and weaker utilization would indicate hospitals are adding capacity ahead of demand and would be especially damaging to the premium valuation. For ABT, the relevant catalyst is not broad revenue growth but the terms, financing, antitrust progress, and synergy assumptions around EXAS; any upward revision to expected integration costs or litigation reserves could absorb the apparent valuation discount.

Consensus likely underestimates the asymmetry: ISRG’s moat is real, but market expectations increasingly treat it as immune to normal hospital-budget cycles and emerging robotic competition. The contrarian case is that ABT can outperform on a relative basis without a major operational acceleration if ISRG merely re-rates toward a lower growth multiple. This is a 3-6 month relative-value setup rather than a high-conviction directional healthcare call.

Key Decisions for Investors

• Initiate a market-neutral pair: long ABT / short ISRG in equal dollar amounts for 3-6 months. Target 10-15% relative outperformance from ISRG multiple normalization and ABT’s lower expectations; exit if ISRG sustains procedure growth above guidance while raising full-year gross-margin or EPS guidance.
• Do not add outright ABT exposure ahead of definitive EXAS financing, regulatory, and synergy disclosure. Treat confirmation of limited dilution and manageable integration costs as the trigger to convert the pair’s ABT leg into a standalone long.
• For existing ISRG longs, trim into strength and retain upside through a defined-risk call spread rather than unhedged equity. The thesis is falsified by continued utilization-led growth, not merely system placements, through the next two quarterly reports.
• Monitor MDT and JNJ robotic-surgery commercialization milestones as competitive alerts rather than immediate shorts. Evidence of pricing concessions, rising hospital evaluations of alternative platforms, or ISRG procedure-share slippage would strengthen the ABT/ISRG relative short leg.